Morningstar

Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, met its primary endpoint in a head-to-head Phase 3 trial versus Imbruvica ...

BRUIN CLL-314 is the first-ever head-to-head Phase 3 study versus a covalent BTK inhibitor to include treatment-naïve patients INDIANAPOLIS, July 29, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: ...
Morningstar

Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, significantly improved progression-free survival in patients with ...

In the Phase 3 BRUIN CLL-313 study, treatment with pirtobrutinib demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival versus bendamustine ...
Medscape

EMA Says Active Substance in Tardive Dyskinesia Drug Not New

New draft guidelines on the definition of new active substances don’t apply to deutetrabenazine, the European drug regulator ...
Pulmonology Advisor

Brensocatib Beneficial in Bronchiectasis Regardless of Patient’s COPD Status

Brensocatib was associated with decreased exacerbation rates in patients with non-CF bronchiectasis, even in those with ...

Bayer’s New Clinical Study on HER2-Targeting Cancer Treatment: Key Insights for Investors

Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.
Medpage Today on MSN

Novel HER2 Drug Shrinks Lung Cancer Tumors in Early Trial

Approved targeted drugs for HER2 -mutant NSCLC include trastuzumab deruxtecan (T-DXd, Enhertu) -- which is highly effective ...